Cargando…

Earlier is better when treating rheumatoid arthritis: but can we detect a window of opportunity?

OBJECTIVES: The window of opportunity (WOO) hypothesis suggests a limited time frame to stop rheumatoid arthritis (RA). We hypothesised that a WOO could either be represented by a hyperbolic (‘curved’) decline in the chance to achieve the outcome sustained drug-free remission (sDFR) over time, after...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bergstra, Sytske Anne, Van Der Pol, Joy A, Riyazi, Naghmeh, Goekoop-Ruiterman, Yvonne P M, Kerstens, Pit J S M, Lems, Willem, Huizinga, Tom W J, Allaart, Cornelia F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Rheumatoid Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299505/ https://www.ncbi.nlm.nih.gov/pubmed/32471854 http://dx.doi.org/10.1136/rmdopen-2020-001242

Ejemplares similares

Frequency of joint inflammation is associated with local joint damage progression in rheumatoid arthritis despite long-term targeted treatment
por: Heckert, Sascha L, et al.
Publicado: (2023)

Comparison between low disease activity or DAS remission as treatment target in patients with early active rheumatoid arthritis
por: Akdemir, Gülşah, et al.
Publicado: (2018)

Effectiveness of four dynamic treatment strategies in patients with anticitrullinated protein antibody-negative rheumatoid arthritis: a randomised trial
por: Akdemir, G, et al.
Publicado: (2016)

Repair of joint damage in patients with rheumatoid arthritis does not relate to previous suppression of inflammation: a subanalysis after 8 years treat-to-target in the BeSt-trial
por: van der Pol, Joy Ardjuna, et al.
Publicado: (2023)

Individual patient data meta-analysis on continued use of glucocorticoids after their initiation as bridging therapy in patients with rheumatoid arthritis
por: van Ouwerkerk, Lotte, et al.
Publicado: (2023)

Impact of the combined presence of erosions and ACPA on rheumatoid arthritis disease activity over time: results from the METEOR registry
por: Bergstra, Sytske Anne, et al.
Publicado: (2019)

Body mass index and treatment survival in patients with RA starting treatment with TNFα-inhibitors: long-term follow-up in the real-life METEOR registry
por: Bergstra, Sytske Anne, et al.
Publicado: (2020)

Age affects joint space narrowing in patients with early active rheumatoid arthritis
por: Matthijssen, X M E, et al.
Publicado: (2016)

Evaluation of the joint distribution at disease presentation of patients with rheumatoid arthritis: a large study across continents
por: Bergstra, Sytske Anne, et al.
Publicado: (2017)

Cost-utility of COBRA-light versus COBRA therapy in patients with early rheumatoid arthritis: the COBRA-light trial
por: ter Wee, Marieke M, et al.
Publicado: (2017)

Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial
por: Boers, Maarten, et al.
Publicado: (2022)

Association Between Bone Mineral Density and Autoantibodies in Patients With Rheumatoid Arthritis
por: Amkreutz, Josephine A. M. P., et al.
Publicado: (2021)

Positive impact on 10-year outcome of the window of opportunity for conventional synthetic DMARDs in rheumatoid arthritis: results from the ESPOIR cohort
por: Kedra, Joanna, et al.
Publicado: (2022)

Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study
por: Jansen, Diahann T S L, et al.
Publicado: (2018)

IgG Anti–Citrullinated Protein Antibody Variable Domain Glycosylation Increases Before the Onset of Rheumatoid Arthritis and Stabilizes Thereafter: A Cross‐Sectional Study Encompassing ~1,500 Samples
por: Kissel, Theresa, et al.
Publicado: (2022)

To treat or not to treat? Current attitudes on treatment aimed at modifying the disease burden in clinically suspect arthralgia: a survey among participants of the TREAT EARLIER trial and healthcare professionals
por: Krijbolder, Doortje I, et al.
Publicado: (2023)

The Effect of Discontinuing Denosumab in Patients With Rheumatoid Arthritis Treated With Glucocorticoids
por: Saag, Kenneth G., et al.
Publicado: (2022)

Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration
por: Lauper, Kim, et al.
Publicado: (2022)

Is there room for better screening for lung cancer in rheumatoid arthritis?
por: Gialouri, Chrysoula G, et al.
Publicado: (2022)

Efficacy of etanercept in combination with methotrexate in moderate-to-severe rheumatoid arthritis is not dependent on methotrexate dosage
por: Gallo, G, et al.
Publicado: (2016)

Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time
por: Boone, Niels W., et al.
Publicado: (2019)

Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects
por: Smolen, Josef S, et al.
Publicado: (2021)

Fatigue in rheumatoid arthritis; a persistent problem: a large longitudinal study
por: van Steenbergen, Hanna W, et al.
Publicado: (2015)

Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study
por: Emery, Paul, et al.
Publicado: (2019)

Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis
por: Fleischmann, Roy M, et al.
Publicado: (2016)

Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study
por: Schiff, Michael, et al.
Publicado: (2015)

Role of Anti–Carbamylated Protein Antibodies Compared to Anti–Citrullinated Protein Antibodies in Indigenous North Americans With Rheumatoid Arthritis, Their First‐Degree Relatives, and Healthy Controls
por: Koppejan, H., et al.
Publicado: (2016)

The Role of Genetics in Clinically Suspect Arthralgia and Rheumatoid Arthritis Development: A Large Cross‐Sectional Study
por: Maurits, Marc P., et al.
Publicado: (2022)

N‐Linked Glycans in the Variable Domain of IgG Anti–Citrullinated Protein Antibodies Predict the Development of Rheumatoid Arthritis
por: Hafkenscheid, Lise, et al.
Publicado: (2019)

Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritis
por: Wu, Chun, et al.
Publicado: (2022)

Antibodies against advanced glycation end-products and malondialdehyde-acetaldehyde adducts identify a new specific subgroup of hitherto patients with seronegative arthritis with a distinct clinical phenotype and an HLA class II association
por: van den Beukel, Michelle D, et al.
Publicado: (2023)

Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib
por: Kay, Jonathan, et al.
Publicado: (2020)

'Difficult to treat' rheumatoid arthritis: current position and considerations for next steps
por: Tan, Yvonne, et al.
Publicado: (2022)

Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity
por: Curtis, Jeffrey R, et al.
Publicado: (2012)

Predictive factors of radiological progression after 2 years of remission-steered treatment in early arthritis patients: a post hoc analysis of the IMPROVED study
por: Akdemir, Gülşah, et al.
Publicado: (2016)

A Randomized Trial Comparing Disease Activity Measures for the Assessment and Prediction of Response in Rheumatoid Arthritis Patients Initiating Certolizumab Pegol
por: Curtis, Jeffrey R., et al.
Publicado: (2015)

Little Evidence for Usefulness of Biomarkers for Predicting Successful Dose Reduction or Discontinuation of a Biologic Agent in Rheumatoid Arthritis: A Systematic Review
por: Tweehuysen, Lieke, et al.
Publicado: (2017)

Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39
por: Spiliopoulou, Athina, et al.
Publicado: (2019)

What do patients prefer? A multinational, longitudinal, qualitative study on patient-preferred treatment outcomes in early rheumatoid arthritis
por: Van der Elst, Kristien, et al.
Publicado: (2020)

Subcutaneous Abatacept vErsus Intravenous Abatacept: A Phase IIIb Noninferiority Study in Patients With an Inadequate Response to Methotrexate
por: Genovese, M C, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_r7v5qp71aitnn5v9r9ke0vm9cv